請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/53737
標題: | 針對抗藥性非小細胞肺癌之嘌呤類化合物的研究 Purine-type Compounds Targeting Gefitnib-resistant Non-Small Cell Lung Cancer |
作者: | Ling-Wei Li 李苓瑋 |
指導教授: | 方俊民 |
關鍵字: | 肺癌,抗藥性, Lung cancer,drug resistance, |
出版年 : | 2015 |
學位: | 碩士 |
摘要: | 肺癌高居全世界人類癌症死亡原因的榜首,每年約有百萬人死於肺癌,約佔癌症死亡率的27%。依照細胞型態的不同,肺癌又分成小細胞肺癌及非小細胞肺癌。被確診為肺癌的患者,其中85%屬於非小細胞肺癌。埃羅替尼(erlotinib)及吉非替尼(gefitinib)為美國食品和藥物管理局及日本所認可之用來針對非小細胞肺癌的標把藥物,但患者經過此種藥物的治療後一年會產生抗藥性。因此,尋找新型態藥物針對抗藥性的肺癌顯得更為重要。 2012年,由中央研究院基因體中心利用高通量藥物篩選系統從兩百萬種化合物資料庫中篩選出幾個先導化合物,其針對抗藥性及非抗藥性的非小細胞肺癌細胞株都有好的抑制效果,我們從中選一個嘌呤類的化合物為目標化合物,但其實際的抑制機制並不明確。在本篇論文中,我們合成了許多嘌呤類化合物的衍生物用來探討結構與活性之間的關係,並尋找適當的位置修飾上帶有生物素(biotin)的官能基,藉由嘌呤類化合物末端帶有生物素的官能基與抗生物素蛋白鏈菌素(streptavidin)之間的強作用力來尋找目標蛋白質。另外,我們所合成的一些嘌呤類化合物衍生物在生物實驗當中有好的抗癌效果。 Lung cancer remains a leading cause of cancer-related mortality in the world, estimated 1.3 million deaths per year to account for more than one-quarter (27%) of all cancer deaths. Lung cancer can be classified into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) according to the histological types, and almost 85% of lung cancer is diagnosed as NSCLC. Erlotinib and gefitinib, which belong to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, have been approved for the treatment of lung cancer by U.S. Food and Drug Administration (FDA) and in Japan. However, most patients may develop drug resistance and relapse one year after treatment. Thus, identifying new potent molecules for drug-resistant lung cancer treatment becomes an important therapeutic objective. Several NSCLC cell lines are used to select potent anticancer agents that may target either EGFR dependent or independent NSCLC. A purine-type compound was found as a hit by the high throughput screening against a library of two-million compounds in the Genomics Research Center (GRC) at Academia Sinica. In this thesis, we first report the synthesis of many purine-type compounds to study the structure–active relationship in an attempt to find better inhibitors. After finding the appropriate position for further modification of the purine-type compound, we also synthesized derivatives with a photoaffinity probe and a biotin label.. Through the collaboration with College of Medicine, National Taiwan University, the biotin-annexed compound was successfully used as a probe to catch the target proteins. Some of our synthesized purine-type compounds demonstrated good anticancer effects in the in vitro and in vivo assays. Further studies are ongoing to explore the purine-type compounds for a new therapy of drug-resistant NSCLC patients. |
URI: | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/53737 |
全文授權: | 有償授權 |
顯示於系所單位: | 化學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 10.33 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。